ZYTIGA — Sales to customers (Note 9)
Products & Services · Sales to customers (Note 9)Johnson & Johnson ZYTIGA — Sales to customers (Note 9) decreased by 22.1% to $226.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 24.4%, from $299.00M to $226.00M. Over 2 years (FY 2021 to FY 2024), ZYTIGA — Sales to customers (Note 9) shows a downward trend with a -49.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market adoption or successful commercialization of the product, while a decrease may signal patent expiration, increased generic competition, or declining market demand.
Detailed definition
This metric represents the total net revenue generated from the sale of the specific pharmaceutical product ZYTIGA to ex...
Peer comparison
Comparable to specific product line revenue metrics reported by other pharmaceutical companies, often found in segment reporting or product-level disclosures.
jnj_segment_zytiga_sales_to_customers_note_9Historical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.28B | $1.13B | $1.10B | $1.59B | $1.08B | $1.01B | $912.00M | $490.00M | $429.00M | $362.00M | $330.00M | $299.00M | $271.00M | $250.00M | $290.00M | $226.00M |
| QoQ Change | — | -11.8% | -2.7% | +45.4% | -32.4% | -6.3% | -9.7% | -46.3% | -12.4% | -15.6% | -8.8% | -9.4% | -9.4% | -7.7% | +16.0% | -22.1% |
| YoY Change | — | — | — | — | -15.5% | -10.3% | -16.8% | -54.5% | -57.5% | — | -32.7% | -30.3% | — | -30.9% | -12.1% | -24.4% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's zytiga — sales to customers (note 9)?
- Johnson & Johnson (JNJ) reported zytiga — sales to customers (note 9) of $226.00M in Q3 2025.
- How has Johnson & Johnson's zytiga — sales to customers (note 9) changed year-over-year?
- Johnson & Johnson's zytiga — sales to customers (note 9) decreased by 24.4% year-over-year, from $299.00M to $226.00M.
- What is the long-term trend for Johnson & Johnson's zytiga — sales to customers (note 9)?
- Over 2 years (2021 to 2024), Johnson & Johnson's zytiga — sales to customers (note 9) has grown at a -49.5% compound annual growth rate (CAGR), from $4.94B to $1.26B.
- What does zytiga — sales to customers (note 9) mean?
- The total revenue earned from selling the ZYTIGA pharmaceutical product to customers.